Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Cowen & Co. Downgrades PhaseBio Pharmaceuticals to Market Perform

Cowen & Co. Downgrades PhaseBio Pharmaceuticals to Market Perform

Cowen & Co. analyst Phil Nadeau downgrades PhaseBio Pharmaceuticals (NASDAQ:PHAS) from Outperform to Market Perform.

October 24, 2022

1 minute read

Cowen & Co. analyst Phil Nadeau downgrades PhaseBio Pharmaceuticals (NASDAQ:PHAS) from Outperform to Market Perform.

DA Davidson Downgrades Paylocity Holding to Neutral, Announces $250 Price Target

October 28, 7:11 AM

DA Davidson analyst Robert Simmons downgrades Paylocity Holding (NASDAQ:PCTY) from Buy to Neutral and announces $250 price target.

November 10, 8:41 AM

Alibaba Group Holding Limited (NYSE: BABA) has its hands full as it remains engaged in battling

October 9, 7:07 AM

Tesla stock could see weakness on Monday, as traders react to the Middle East tensions and some company-specific concerns.

October 14, 7:35 AM

Raymond James analyst Dane Leone maintains LianBio (NASDAQ:LIAN) with a Outperform and lowers the price target from $27 to $15.